ONCAT CNS GLIOMA A221101 ARMODANFINIL (250 MG) OR PLACEBO - PRL8975
Armodafinil (250 mg) or placebo PO daily x 8 weeks

Build 1 cycle = 56 days
 
Provider Reminders
Corticosteroids are allowed if dose has been stable over previous 14 days prior to registration.
The following medications are prohibited during the study (unless utilized to treat a drug related adverse event):
Medications for ADHD, severe anxiety disorders, schizophrenia or substance abuse.
Medications being used to specifically treat fatigue, including psychostimulants.
Strong CYP3A4 inhibitors.
Moderate CYP3A4 inhibitors.
CYP3A4 inducers.
 
Lab Orders
Baseline Labs: Pregnancy test (females of childbearing potential)
Lab Parameters to Assess: None
Labs Before Each Treatment: None
 
Premedications
Antiemetics Level 1 - No default prophylactic antiemetics
 
Treatment - Take Home
Study A221101: Armodafinil (NUVIGIL) 250 mg Tab or Placebo; QTY #56, Refill: 0
Take 1 tablet by mouth daily for 8 weeks.
For Investigational Use Only.  Use study-supplied medications.  Patient ID#______
Pharmacist to document lot #________
 
Dose Modifications
See section 8.0 for criteria for dose delay/resumption. Refer to section 10.0 for adverse event reporting and management.
 
Nursing Orders
Ensure thorough teaching has been provided to the patient either by the physician, nurse or pharmacist on the potential side effects that may occur while taking study therapy.
Ensure that patient knows to contact healthcare provider when experiencing any of the side effects that can be caused by the study therapy.
Ensure that follow-up visits in clinic or via phone are incrementally scheduled to ensure that the patient is tolerating the study therapy agent and having lab values monitored regularly. 
 
References
Study Title:  A Phase 3 Randomized Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-related Fatigue in Patients with High Grade Glioma
